Translating Cell-Based Regenerative Medicines from Research to Successful Products: Challenges and Solutions

The Tissue Engineering & Regenerative Medicine International Society-Europe (TERMIS-EU) Industry Committee as well as its TERMIS-Americas (AM) counterpart intend to address the specific challenges and needs facing the industry in translating academic research into commercial products. Over the l...

Full description

Saved in:
Bibliographic Details
Published inTissue engineering. Part B, Reviews Vol. 20; no. 4; pp. 246 - 256
Main Authors Bayon, Yves, Vertès, Alain A., Ronfard, Vincent, Egloff, Matthieu, Snykers, Sarah, Salinas, Gabriella Franco, Thomas, Robert, Girling, Alan, Lilford, Richard, Clermont, Gaelle, Kemp, Paul
Format Journal Article
LanguageEnglish
Published United States Mary Ann Liebert, Inc 01.08.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The Tissue Engineering & Regenerative Medicine International Society-Europe (TERMIS-EU) Industry Committee as well as its TERMIS-Americas (AM) counterpart intend to address the specific challenges and needs facing the industry in translating academic research into commercial products. Over the last 3 years, the TERMIS-EU Industry Committee has worked with commercial bodies to deliver programs that encourage academics to liaise with industry in proactive collaborations. The TERMIS-EU 2013 Industry Symposium aimed to build on this commercial agenda by focusing on two topics: Operations Management (How to move a process into the good manufacturing practice [GMP] environment) and Clinical Translation (Moving a GMP process into robust trials). These topics were introduced by providing the synergistic business perspective of partnering between the multiple regenerative medicine stakeholders, throughout the life cycle of product development. Seven industry leaders were invited to share their experience, expertise, and strategies. Due to the complex nature of regenerative medicine products, partnering for their successful commercial development seems inevitable to overcome all obstacles by sharing experiences and expertise of all stakeholders. When ideally implemented, the “ innovation quotient ” of a virtual team resulting from the combination of internal and external project teams can be maximized through maximizing the three main dimensions: core competences, technology portfolio, and alliance management.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1937-3368
1937-3376
DOI:10.1089/ten.teb.2013.0727